Proper handling at-a-glance

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

Proper handling of the YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg packaging is a necessary step for successful administration and helps to prevent unintentionally damaging, contaminating, or dislodging the implant. Keep the 4 steps below top-of-mind when handling YUTIQ.

FOR INFORMATIONAL PURPOSES ONLY—THE PURPOSE OF THIS RESOURCE IS TO INFORM YOU OF THE PROPER OPENING AND HANDLING OF THE YUTIQ PACKAGING AND APPLICATOR, RESPECTIVELY. THE INTRAVITREAL INJECTION PROCEDURE SHOULD BE CARRIED OUT UNDER ASEPTIC CONDITIONS AS IN THE FULL PRESCRIBING INFORMATION.

Using aseptic procedure, carefully open the YUTIQ carton. Do not use scissors or any sharp objects when opening the carton.[1]



Open the sealed Tyvek and sterile pouches completely, exposing the entire applicator to ensure you remove the applicator from its packaging correctly.[1]

Remove the applicator by the barrel; this will prevent the plunger from moving backward, resulting in an unusable applicator.[1]



With the YUTIQ applicator above the horizontal plane, remove the black stopper from the plunger. Be gentle when removing the black stopper, so as not to remove or cause damage to the plunger.[1]

INDICATIONS AND USAGE

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.

Please see additional Important Safety Information on reverse.

For more on proper handling and administration, please visit YUTIQ.com

Proper handling at-a-glance

Do's and don'ts when handling and unpacking

DO

- Use aseptic procedure
- Open sterile packaging completely, exposing the entire applicator
- Remove the applicator from the packaging only grasping the barrel
- Always keep the applicator tip above the horizontal plane until you're ready to inject

DON'T

- Cut the carton in any way to open it
- Partially open the sterile pouch
- Grasp the plunger when removing the applicator from its pouch
- Let the needle tip tilt below the horizontal plane risking the insert falling out

For more information about handling the YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg applicator or the complete administration process, please contact your sales representative or call 1-833-EyePoint (1-833-393-7646), option 2.

IMPORTANT SAFETY INFORMATION (*cont'd*)

WARNINGS AND PRECAUTIONS

Intravitreal Injection-related Effects: Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.

Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

ADVERSE REACTIONS

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Reference: 1. YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. EyePoint Pharmaceuticals, Inc. October 2018.

Please see full Prescribing Information in pocket.

EyePoint PHARMACEUTICALS

07/2020
US-YUT-2000063